Ensuring Patient Access to Critical Breakthrough Products Act of 2023

Rate

AI Summary: The "Ensuring Patient Access to Critical Breakthrough Products Act of 2023" aims to improve patient access to innovative medical products by streamlining the approval process for breakthrough therapies. The bill proposes provisions to expedite the review and approval of breakthrough products by the Food and Drug Administration (FDA), ensuring timely access for patients in need. This legislation seeks to enhance collaboration between stakeholders, facilitate efficient regulatory pathways, and promote innovation in the healthcare industry. If enacted, this bill could lead to faster availability of cutting-edge treatments and better outcomes for patients with serious or life-threatening conditions.

Latest Action: Introduced in House

Comments Contributions Actions (7) Sponsors (1) Cosponsors (87) Text Versions (1) Roll Calls (0) Amendments (0) View All

Contributions (0)

Contribute Your Insights: Add a Unique Perspective to Political Bills. Your Contribution will be Featured Below the Primary Bill, Ordered by Date Added.

Actions (7):

2023-03-22 : Introduced in House
2023-03-22 : Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2023-03-31 : Referred to the Subcommittee on Health.
2023-11-15 : Subcommittee Consideration and Mark-up Session Held
2023-11-15 : Forwarded by Subcommittee to Full Committee by the Yeas and Nays: 21 - 6.
2024-06-27 : Committee Consideration and Mark-up Session Held
2024-06-27 : Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 36 - 5.